search
Back to results

Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation

Primary Purpose

Infertility

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
INVOcell Culture Device
IVF Incubation
Sponsored by
Invaron Pharmaceuticals Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring intravaginal culture, in vitro fertilization, blastocyst, pregnancy

Eligibility Criteria

18 Years - 38 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Couples who will participate to the study will be pre selected for the following major indications:

Women diagnosed with:

  • Tubal factor
  • Endometriosis (type I to II)
  • Ovulatory dysfunction (slight)
  • Multiple female factors (<2)

Males with slight male factor

Couples with:

  • Unknown factor
  • Multiple factors, from female and male origin (<2)
  • Other rare factors not excluded by the inclusion/exclusion criteria (e.g. cervical mucus immune factor not treatable by IUI)

The pre-selected couples will be included in the study only if they fulfill the more specific inclusion and exclusion criteria below.

Couples may be included in the study only if they have been informed about the study and have given their written consent.

Infertile couple with failure to conceive a recognized pregnancy after one year (or 12 menstrual cycles) of unprotected intercourse IVF has been determined by the physician to be their next treatment

Women included in the study should:

  • Be between the age of 18 and 38 (up to 38th birthday at the time of the enrollment).
  • Have had a normal gynecological examination and Pap smear in the last 12 months.
  • Have a normal follicle stimulating hormone (<10 mIU/mL) and E2 (<250 pmol/L) on Day 3, determined in the past 12 months
  • Have an anti-mullerian hormone >1 or <3 ng/mL
  • Have had a normal baseline pelvic ultrasound examination in the past 12 months
  • Have a normal uterine cavity as assessed in the past year by hysterosalpingogram, sonohysterography or hysteroscopy. Prior tubal ligation is acceptable.
  • Have had negative cervical tests for G.C and Chlamydia in the past 12 months. Have male partner with a normal semen analysis with a total number of > 15 million total motile spermatozoa with normal morphology or borderline normal morphology (> 3% with the strict criteria) and a progression rating of >2.

Exclusion Criteria:

Women to be excluded from this study are those who have:

  • Inability to read and speak English fluently
  • A history of recurrent vaginitis
  • A history of toxic shock syndrome
  • Known allergies to plastic, human serum proteins or gentamicin
  • Had pelvic surgery within the past 8 weeks, excluding diagnostic laparoscopy
  • Pelvic inflammatory disease (PID) within the past 3 months and were treated with antibiotics
  • Severe endometriosis (stage III-IV) or endometriomas (past or present)
  • Clinical signs of vaginal infection
  • Significant abnormalities of the vaginal cavity
  • Sub mucus or intramural fibroids (>1 cm diameter)
  • Hydrosalpinx
  • Chronic illness, e.g. autoimmune disease, diabetes
  • BMI >36
  • Donor oocytes, donor sperm
  • antral follicle count < 6 or > 20
  • Anti-Mullerian Hormone <1 or >3
  • Previously responded poorly to ovarian stimulation and polycystic ovary patients
  • High responder to ovarian stimulation
  • Cervical stenosis, as demonstrated by failed mock embryo transfer
  • Cannot tolerate a speculum examination
  • Unwilling or unable to wear a retention system (diaphragm) during the 5 days of incubation.

> 2 previously failed IVF (neg βhCG)

  • Previously failed fertilization of all oocytes previous IVF cycle
  • Smoke or abuse drugs and alcohol
  • Poor understanding of the procedure
  • Partner with vasectomy reversal
  • Partner with difficulty in producing sperm specimen
  • Partner with uro-genital infection. Sperm culture will be performed if the partner shows or has shown some symptoms of uro-genital infection.

Sites / Locations

  • C.A.R.E.

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Active Comparator

Arm Label

Medical Device: INVOcell Culture Device

Medical Device: IVF Incubator

Arm Description

5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.

5 day oocyte incubation using traditional IVF incubation.

Outcomes

Primary Outcome Measures

Blastocyst Quality
Blastocyst generation rate: number of day 5 embryos of "good quality" defined as 2BB or greater (expansion of embryo 2,3,4,5 or 6 and inner cell mass and outer cell mass grades of A or B) or higher using the Gardner Grading System divided by the number of eggs incubated

Secondary Outcome Measures

Patient Acceptability
Patient acceptability of INVOcell and intravaginal culture using a 12 point subjective and quantitative questionnaire.
Live Birth Rate
Live birth rate: number of cycles with a live birth divided by the number of cycles with embryo transfers.
Clinical Pregnancy Rate
Clinical pregnancy rate: number of cycles with fetal heartbeat at week 7 divided by the number of cycles with embryo transfers.
Fertilization Rate
Fertilization rate: Number of embryos obtained after incubation divided by the number of oocytes placed in the device.
Embryo Transfer Rate
Embryo transfer rate: Number of cycles initiated divided by the number of cycles with embryo transfers
Miscarriage Rate
Miscarriage rate: Number of miscarriages divided by the number of cycles with embryo transfers
Multiple Rate
Multiple rate: Number cycles with twins or triplets divided by the number of cycles with embryo transfers

Full Information

First Posted
February 5, 2015
Last Updated
January 18, 2016
Sponsor
Invaron Pharmaceuticals Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02363426
Brief Title
Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation
Official Title
Randomized Controlled Open-Label Non-Inferiority Trial Comparing Day 5 Embryos Derived From Intravaginal Culture Using the Medical Device INVOcell to Traditional In Vitro Fertilization
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
January 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Invaron Pharmaceuticals Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate intravaginal culture using the medical device INVOcell to generate day 5 blastocysts in comparison to traditional IVF.
Detailed Description
This is a Phase III, single center, open label randomized comparative trial to evaluate intravaginal culture using INVOcell vs. traditional IVF to generate day 5 embryos Pilot: 40 couples (80 patients), randomized to receive either intravaginal culture (n=20) using the INVOcell or traditional IVF (n=20) Primary Endpoints: Blastocyst generation rate: number of day 5 embryos of "good quality" defined as 2BB or greater (expansion of embryo 2,3,4,5 or 6 and inner cell mass and outer cell mass grades of A or B) or higher using the Gardner Grading System divided by the number of eggs incubated Patient acceptability of INVOcell and intravaginal culture. Secondary Endpoints: Live birth rate: number of cycles with a live birth divided by the number of cycles with embryo transfers. Clinical pregnancy rate: number of cycles with fetal heartbeat at week 7 divided by the number of cycles with embryo transfers. Fertilization rate: Number of embryos obtained after incubation divided by the number of oocytes placed in the device. Embryo transfer rate: Number of cycles initiated divided by the number of cycles with embryo transfers Miscarriage rate: Number of miscarriages divided by the number of cycles with embryo transfers Multiple rate: Number cycles with twins or triplets divided by the number of cycles with embryo transfers Miscarriage rate per clinical pregnancy: Number of miscarriages divided by the number of cycles with clinical pregnancy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
intravaginal culture, in vitro fertilization, blastocyst, pregnancy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Medical Device: INVOcell Culture Device
Arm Type
Other
Arm Description
5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.
Arm Title
Medical Device: IVF Incubator
Arm Type
Active Comparator
Arm Description
5 day oocyte incubation using traditional IVF incubation.
Intervention Type
Device
Intervention Name(s)
INVOcell Culture Device
Other Intervention Name(s)
INVOcell, INVOcell Culture Device
Intervention Description
INVOcell is a vaginal culture device
Intervention Type
Device
Intervention Name(s)
IVF Incubation
Intervention Description
IVF Incubator
Primary Outcome Measure Information:
Title
Blastocyst Quality
Description
Blastocyst generation rate: number of day 5 embryos of "good quality" defined as 2BB or greater (expansion of embryo 2,3,4,5 or 6 and inner cell mass and outer cell mass grades of A or B) or higher using the Gardner Grading System divided by the number of eggs incubated
Time Frame
Measures assessed following 5 days incubation, approximately 17 days following randomization
Secondary Outcome Measure Information:
Title
Patient Acceptability
Description
Patient acceptability of INVOcell and intravaginal culture using a 12 point subjective and quantitative questionnaire.
Time Frame
Measures assessed at first followup visit following embryo transfer, approximately 9 weeks post randomization
Title
Live Birth Rate
Description
Live birth rate: number of cycles with a live birth divided by the number of cycles with embryo transfers.
Time Frame
Measures assessed 9 months post embryo transfer, approximately 9 months and two weeks following randomization
Title
Clinical Pregnancy Rate
Description
Clinical pregnancy rate: number of cycles with fetal heartbeat at week 7 divided by the number of cycles with embryo transfers.
Time Frame
Measures assessed approximately 16 days following embryo transfer, approximately 4 weeks following randomization.
Title
Fertilization Rate
Description
Fertilization rate: Number of embryos obtained after incubation divided by the number of oocytes placed in the device.
Time Frame
Measures assessed following 5 days post incubation, approximately 2 and 1/2 weeks post randomization.
Title
Embryo Transfer Rate
Description
Embryo transfer rate: Number of cycles initiated divided by the number of cycles with embryo transfers
Time Frame
Measures assessed following 5 days incubation, approximately 2 and 1/2 weeks following randomization.
Title
Miscarriage Rate
Description
Miscarriage rate: Number of miscarriages divided by the number of cycles with embryo transfers
Time Frame
Measures assessed following embryo transfer and a maximum of 9 months gestation.
Title
Multiple Rate
Description
Multiple rate: Number cycles with twins or triplets divided by the number of cycles with embryo transfers
Time Frame
Measures assessed 9 months after the last subject received an embryo transfer, once all live birth data is known for each embryo.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
38 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Couples who will participate to the study will be pre selected for the following major indications: Women diagnosed with: Tubal factor Endometriosis (type I to II) Ovulatory dysfunction (slight) Multiple female factors (<2) Males with slight male factor Couples with: Unknown factor Multiple factors, from female and male origin (<2) Other rare factors not excluded by the inclusion/exclusion criteria (e.g. cervical mucus immune factor not treatable by IUI) The pre-selected couples will be included in the study only if they fulfill the more specific inclusion and exclusion criteria below. Couples may be included in the study only if they have been informed about the study and have given their written consent. Infertile couple with failure to conceive a recognized pregnancy after one year (or 12 menstrual cycles) of unprotected intercourse IVF has been determined by the physician to be their next treatment Women included in the study should: Be between the age of 18 and 38 (up to 38th birthday at the time of the enrollment). Have had a normal gynecological examination and Pap smear in the last 12 months. Have a normal follicle stimulating hormone (<10 mIU/mL) and E2 (<250 pmol/L) on Day 3, determined in the past 12 months Have an anti-mullerian hormone >1 or <3 ng/mL Have had a normal baseline pelvic ultrasound examination in the past 12 months Have a normal uterine cavity as assessed in the past year by hysterosalpingogram, sonohysterography or hysteroscopy. Prior tubal ligation is acceptable. Have had negative cervical tests for G.C and Chlamydia in the past 12 months. Have male partner with a normal semen analysis with a total number of > 15 million total motile spermatozoa with normal morphology or borderline normal morphology (> 3% with the strict criteria) and a progression rating of >2. Exclusion Criteria: Women to be excluded from this study are those who have: Inability to read and speak English fluently A history of recurrent vaginitis A history of toxic shock syndrome Known allergies to plastic, human serum proteins or gentamicin Had pelvic surgery within the past 8 weeks, excluding diagnostic laparoscopy Pelvic inflammatory disease (PID) within the past 3 months and were treated with antibiotics Severe endometriosis (stage III-IV) or endometriomas (past or present) Clinical signs of vaginal infection Significant abnormalities of the vaginal cavity Sub mucus or intramural fibroids (>1 cm diameter) Hydrosalpinx Chronic illness, e.g. autoimmune disease, diabetes BMI >36 Donor oocytes, donor sperm antral follicle count < 6 or > 20 Anti-Mullerian Hormone <1 or >3 Previously responded poorly to ovarian stimulation and polycystic ovary patients High responder to ovarian stimulation Cervical stenosis, as demonstrated by failed mock embryo transfer Cannot tolerate a speculum examination Unwilling or unable to wear a retention system (diaphragm) during the 5 days of incubation. > 2 previously failed IVF (neg βhCG) Previously failed fertilization of all oocytes previous IVF cycle Smoke or abuse drugs and alcohol Poor understanding of the procedure Partner with vasectomy reversal Partner with difficulty in producing sperm specimen Partner with uro-genital infection. Sperm culture will be performed if the partner shows or has shown some symptoms of uro-genital infection.
Facility Information:
Facility Name
C.A.R.E.
City
Beford
State/Province
Texas
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
3350160
Citation
Ranoux C, Aubriot FX, Dubuisson JB, Cardone V, Foulot H, Poirot C, Chevallier O. A new in vitro fertilization technique: intravaginal culture. Fertil Steril. 1988 Apr;49(4):654-7. doi: 10.1016/s0015-0282(16)59835-5.
Results Reference
background

Learn more about this trial

Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation

We'll reach out to this number within 24 hrs